➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Harvard Business School
McKinsey
Dow
Moodys

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for HGP0904


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug HGP0904?

HGP0904 is an investigational drug.

There have been 7 clinical trials for HGP0904. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Hypertension, Dyslipidemias, and Hyperlipidemias. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Seoul National University Bundang Hospital, and [disabled in preview].

There is one US patent protecting this investigational drug and twenty-three international patents.

Recent Clinical Trials for HGP0904
TitleSponsorPhase
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and DyslipidemiaHanmi Pharmaceutical Company LimitedPhase 3
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.Hanmi Pharmaceutical Company LimitedPhase 1
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.Hanmi Pharmaceutical Company LimitedPhase 1

See all HGP0904 clinical trials

Clinical Trial Summary for HGP0904

Top disease conditions for HGP0904
Top clinical trial sponsors for HGP0904

See all HGP0904 clinical trials

US Patents for HGP0904

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HGP0904   Get Started Free Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA)   Get Started Free
HGP0904   Get Started Free Matrix and layer compositions for protection of bioactives Novus International, Inc. (St. Charles, MO)   Get Started Free
HGP0904   Get Started Free Compositions and methods of use of phorbol esters for the treatment of stroke Biosuccess Biotech Co. Ltd. (Santa Clara, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for HGP0904

Drugname Country Document Number Estimated Expiration Related US Patent
HGP0904 European Patent Office EP2981556 2033-04-02   Get Started Free
HGP0904 World Intellectual Property Organization (WIPO) WO2014165513 2033-04-02   Get Started Free
HGP0904 Australia AU2013290122 2032-07-12   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.